JP7723457B2 - 細胞膜透過性を有するペプチドおよびそのスクリーニング方法 - Google Patents

細胞膜透過性を有するペプチドおよびそのスクリーニング方法

Info

Publication number
JP7723457B2
JP7723457B2 JP2025515752A JP2025515752A JP7723457B2 JP 7723457 B2 JP7723457 B2 JP 7723457B2 JP 2025515752 A JP2025515752 A JP 2025515752A JP 2025515752 A JP2025515752 A JP 2025515752A JP 7723457 B2 JP7723457 B2 JP 7723457B2
Authority
JP
Japan
Prior art keywords
amino acid
peptide
cells
drug
cdna display
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025515752A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2025009503A1 (https=
JPWO2025009503A5 (https=
Inventor
充訓 原田
幸一郎 北村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MESCUE-JANUSYS INC.
Original Assignee
MESCUE-JANUSYS INC.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MESCUE-JANUSYS INC. filed Critical MESCUE-JANUSYS INC.
Publication of JPWO2025009503A1 publication Critical patent/JPWO2025009503A1/ja
Publication of JPWO2025009503A5 publication Critical patent/JPWO2025009503A5/ja
Application granted granted Critical
Publication of JP7723457B2 publication Critical patent/JP7723457B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
JP2025515752A 2023-07-03 2024-07-01 細胞膜透過性を有するペプチドおよびそのスクリーニング方法 Active JP7723457B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023109588 2023-07-03
JP2023109588 2023-07-03
PCT/JP2024/023780 WO2025009503A1 (ja) 2023-07-03 2024-07-01 細胞膜透過性を有するペプチドおよびそのスクリーニング方法

Publications (3)

Publication Number Publication Date
JPWO2025009503A1 JPWO2025009503A1 (https=) 2025-01-09
JPWO2025009503A5 JPWO2025009503A5 (https=) 2025-06-10
JP7723457B2 true JP7723457B2 (ja) 2025-08-14

Family

ID=94171533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025515752A Active JP7723457B2 (ja) 2023-07-03 2024-07-01 細胞膜透過性を有するペプチドおよびそのスクリーニング方法

Country Status (2)

Country Link
JP (1) JP7723457B2 (https=)
WO (1) WO2025009503A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005013073A (ja) 2003-06-25 2005-01-20 Mitsubishi Pharma Corp 輸送ポリペプチドのスクリーニング方法
WO2006041194A1 (ja) 2004-10-15 2006-04-20 Japan Science And Technology Agency ｍＲＮＡ－ピューロマイシン－タンパク質連結体作製用リンカー
JP2009527251A (ja) 2006-02-20 2009-07-30 エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション 細胞膜透過性ペプチド
JP2019528693A (ja) 2016-09-21 2019-10-17 アマル セラピューティクス エスエー 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体
WO2022238530A1 (en) 2021-05-12 2022-11-17 University Of Copenhagen Psd-95 inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2548807C2 (ru) * 2009-05-20 2015-04-20 Торэй Индастриз, Инк. Пептиды, проникающие в клетку
US10736941B2 (en) * 2015-05-19 2020-08-11 National University Corporation Kumamoto University Cell membrane-permeating peptide
NL2016207B1 (en) * 2016-02-02 2017-08-21 Stichting Katholieke Univ Selective cell penetrating peptides.
EP3597223A1 (en) 2018-07-17 2020-01-22 Centre National De La Recherche Scientifique Peptides for use as cell-penetrating peptides
KR102588548B1 (ko) * 2019-07-16 2023-10-16 주식회사 젠센 자가면역질환 및 염증성질환 펩타이드 치료제
JP7578991B2 (ja) * 2019-08-28 2024-11-07 国立研究開発法人理化学研究所 細胞膜透過性ベシクル

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005013073A (ja) 2003-06-25 2005-01-20 Mitsubishi Pharma Corp 輸送ポリペプチドのスクリーニング方法
WO2006041194A1 (ja) 2004-10-15 2006-04-20 Japan Science And Technology Agency ｍＲＮＡ－ピューロマイシン－タンパク質連結体作製用リンカー
JP2009527251A (ja) 2006-02-20 2009-07-30 エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション 細胞膜透過性ペプチド
JP2019528693A (ja) 2016-09-21 2019-10-17 アマル セラピューティクス エスエー 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体
WO2022238530A1 (en) 2021-05-12 2022-11-17 University Of Copenhagen Psd-95 inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2025009503A1 (ja) 2025-01-09
JPWO2025009503A1 (https=) 2025-01-09

Similar Documents

Publication Publication Date Title
EP3341394B1 (en) Improved cell-permeable (icp)-socs3 recombinant protein and uses thereof
EP2480672B1 (fr) Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
KR20240172763A (ko) 핵산 및/또는 단백질 적재물 전달을 위한 조성물 및 방법
EP3518981A1 (en) Delivery of therapeutic rnas via arrdc1-mediated microvesicles
CN103501818A (zh) 用于高效及靶向递送治疗性分子至cxcr4细胞的方法和试剂
WO2012137036A1 (en) Cell penetrating peptides for intracellular delivery of molecules
CN114364704B (zh) 修饰的piggybac转座酶多肽、编码其的多核苷酸、引入载体、试剂盒、将靶序列整合到细胞基因组中的方法以及生产细胞的方法
US20200208177A1 (en) Methods and compositions for genome editing
JP2018064573A (ja) ハイスループットペプチドミメティックを調製するための方法、経口バイオアベイラブルな薬物およびそれを含有する組成物
JP7723457B2 (ja) 細胞膜透過性を有するペプチドおよびそのスクリーニング方法
JP7697656B2 (ja) 人工ウイルスキャプシド
KR20220117091A (ko) 생체내 세포에서 합성 및 분비되고 세포로 투과하는 관심 폴리펩타이드를 코딩하는 발현카세트 및 이의 용도
EP1907544B1 (en) Membrane-translocating peptides
EP3309178A1 (en) Fusion protein or conjugated protein, intracellular delivery carrier, partial peptide, cell membrane permeation enhancer, dna, and vector
TW202348801A (zh) 基於噬菌體展示之細胞穿透肽發現平台及製備及使用其之方法
JP7716101B2 (ja) 細胞内送達ペプチド
JP6454008B2 (ja) 変異型シャペロニン複合体を利用した細胞内への局所的薬物送達システム用ナノカプセル
US20240110202A1 (en) Advanced Cell-Permeable Peptide Carriers
JP7329750B2 (ja) リポソーム結合ペプチド、リポソーム結合ペプチドの作製用コンストラクト及びリポソーム
JP7477886B2 (ja) 核酸アプタマー
Shen Understanding the Biological Barriers to Jurkat Transfection using Non-Viral Peptides
Hofmann Conditional Cell Penetration of a Masked CPP and Optimization of Multimeric CPP-Delivery Modules for Intracellular Cargo Delivery
CN121154846A (zh) 基于功能核酸的纳米胶束在靶向蛋白降解中的应用
Kraß Development of cell-type specific ligands and dendrons comprising a defined number of different functional groups for targeted gene therapy
WO2025005142A1 (ja) 細胞外小胞と連結させて使用するための複合体及びその利用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250314

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250715

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250725

R150 Certificate of patent or registration of utility model

Ref document number: 7723457

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150